13:07 , Jan 17, 2019 |  BC Innovations  |  Emerging Company Profile

Zelluna’s solid TCR plans

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development. CEO...
00:44 , Jan 11, 2019 |  BC Extra  |  Preclinical News

UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop

University of Washington researchers published a Nature paper Wednesday detailing the construction of a synthetic protein that selectively binds to IL-2 to avoid toxicities that have previously overshadowed interest in the receptor as a therapeutic...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8 + T cells pretreated with a tool...
14:01 , Jan 3, 2019 |  BC Innovations  |  Translation in Brief

Neo opportunities in glioblastoma

Phase I results from a consortium led by BioNTech AG and Immatics Biotechnologies GmbH convinced both companies that personalized immunotherapies can turn on T cell activity in glioblastoma, an immunologically "cold" cancer. The study is...
17:04 , Dec 20, 2018 |  BC Innovations  |  Translation in Brief

Beyond T cell counts

While strategies to increase the efficacy of immune checkpoint inhibitors have largely been focused on boosting overall T cell count in the tumor microenvironment, researchers at the Netherlands Cancer Institute (NKI) found that antigen specificity...
18:31 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Synthorx gains following $131M IPO

Synthetic biology company Synthorx Inc. (NASDAQ:THOR) gained $1.61 (15%) to $12.61 on Dec. 7 after raising $131 million late Dec. 6 through the sale of 11.9 million shares at $11 in its bumped-up IPO. The...
18:56 , Dec 13, 2018 |  BC Innovations  |  Translation in Brief

3-D immune response

A Boston Children's Hospital team has developed a 3-D human tissue model that reproduces age-specific immune responses to vaccine antigens and could surmount the hurdles of developing vaccines for neonates and infants. Preclinical vaccine development...
20:19 , Dec 7, 2018 |  BC Extra  |  Financial News

Synthorx gains following $131M IPO

Synthetic biology company Synthorx Inc. (NASDAQ:THOR) gained $1.61 (15%) to $12.61 Friday after raising $131 million late Thursday through the sale of 11.9 million shares at $11 in its bumped-up IPO. The offering values the...
17:51 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

New BCMA-targeted therapies could help sicker patients

Oral abstracts at this year’s American Society of Hematology meeting describing next generation anti-BCMA CARs from Poseida Therapeutics Inc. and Fred Hutchinson Cancer Research Center and a bispecific antibody from Amgen Inc. (NASDAQ:AMGN) hint that...
17:31 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Celgene reports updated ORR of 82% for anti-BCMA CAR T therapy in MM

The Juno Therapeutics Inc. subsidiary of Celgene Corp. (NASDAQ:CELG) reported updated data from the Phase I/II EVOLVE trial to treat relapsed and/or refractory multiple myeloma in patients who have received at least three prior regimens...